Atropos Health Secures $33M in Series B Funding to Enhance Personalized Real-World Evidence


image 2

Atropos Health, a Palo Alto-based company specializing in translating real-world clinical data into high-quality personalized evidence for healthcare, has raised $33 million in Series B funding. This round was led by Valtruis and included new strategic investors such as Cencora Ventures, McKesson Ventures, and Merck GHI Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.

Funding Utilization
The funding will be used to further develop and expand Atropos Health’s capabilities, particularly its Generative AI platform, GENEVA OSTM, which has been widely adopted by healthcare institutions, data platforms, research organizations, and life sciences companies.

Company Background
Founded in 2019 as a spin-out of the “Green Button” technology from Stanford University, Atropos Health was developed by Brigham Hyde, Ph.D., Nigam Shah, MBBS, Ph.D., and Saurabh Gombar, M.D., Ph.D. The company’s mission is to bridge evidence gaps in healthcare and improve patient outcomes through data-driven care.

Technological Focus
Atropos Health’s core technology, the GENEVA OSTM platform, serves as an operating system for rapid generation of healthcare evidence using a network of real-world data. This technology supports healthcare and life science organizations by:

  • Closing evidence gaps from research to clinical application.
  • Enhancing patient outcomes with personalized, data-driven care.
  • Accelerating research to advance medical knowledge.
  • Supporting value-based performance and whole-person care.

Impact and Partnerships
Atropos Health’s evidence-generating applications are designed to improve clinical decision-making, driving high-value, cost-effective care tailored to individual patient physiology. Long-standing partners like Arcadia have benefited from these innovations, leveraging Atropos Health’s platform to deliver improved patient care.

Leadership Commentary
Brigham Hyde, Ph.D., Co-Founder of Atropos Health, highlighted the company’s role in transforming healthcare by making real-world evidence accessible and actionable for providers and researchers. The recent funding will bolster efforts to expand the reach and impact of their technology, ultimately fostering better patient outcomes and advancing the field of medicine.

Atropos Health is positioned to continue leading the integration of real-world data into clinical practice, ensuring that personalized, evidence-based care is a cornerstone of modern healthcare systems.

Related Stories